Literature DB >> 19545538

Neuromyelitis optica: Passive transfer to rats by human immunoglobulin.

Makoto Kinoshita1, Yuji Nakatsuji, Takashi Kimura, Masayuki Moriya, Kazushiro Takata, Tatsusada Okuno, Atsushi Kumanogoh, Koji Kajiyama, Hiroo Yoshikawa, Saburo Sakoda.   

Abstract

Recurrent attacks of optic neuritis and myelitis are the hallmarks of both neuromyelitis optica (NMO) and multiple sclerosis (MS). NMO immunoglobulin G (NMO-IgG), which recognizes astrocytic aquaporin-4 (AQP4) water channels, is a specific serum autoantibody that distinguishes NMO from MS. The pathogenic role of the anti-AQP4 antibody (AQP4-Ab, NMO-IgG) in NMO has been speculated based on several studies in vitro. The aim of this study was to demonstrate the pathogenicity of AQP4-Ab in vivo. We obtained IgG from patients who underwent therapeutic plasmapheresis, and developed an animal model by passive transfer of IgG to rats. The active lesions of the rats exhibited pathological characteristics strikingly similar to those of NMO, marked by astrocytic loss and perivascular deposition of immunoglobulin and complements. These findings provide the first evidence of the pathogenicity of AQP4-Ab in vivo and support the therapeutic efficacy of eliminating the antibodies by plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545538     DOI: 10.1016/j.bbrc.2009.06.085

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  93 in total

Review 1.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

Review 3.  [Therapeutic monoclonal antibodies in clinical neurology].

Authors:  M Buttmann; H Wiendl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

4.  Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients.

Authors:  S Jarius; A Warth; K P Wandinger; P A Schnabel; H Hoffmann; B Wildemann; T Muley
Journal:  Neurol Sci       Date:  2010-05-27       Impact factor: 3.307

5.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

6.  Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Hua Zhang; Samira Saadoun; Puay-Wah Phuan; Chiwah Lam; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman
Journal:  Ann Neurol       Date:  2012-01-23       Impact factor: 10.422

7.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

8.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

9.  Review of Animal Models of Neuromyelitis Optica.

Authors:  Melina V Jones; Nicolas Collongues; Jerome de Seze; Makoto Kinoshita; Yuji Nakatsuji; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

10.  Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.

Authors:  Jordan C Bell; Qingwei Liu; Yan Gan; Qiang Liu; Yaou Liu; Fu-Dong Shi; Gregory H Turner
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.